Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our data indicated that PLCG1 could act as an oncogene in HCC carcinogenesis and could serve as a valuable prognostic marker and potential therapeutic target for HCC.
|
30623526 |
2019 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Notably, PLC-gamma 1 was silenced without affecting the levels of other subtypes of PLC so that the role of PLC-gamma 1 in colon carcinogenesis could be examined.
|
17531112 |
2007 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Phospholipase Cγ1 links inflammation and tumorigenesis in colitis-associated cancer.
|
29464031 |
2018 |
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
By radioimmunoassay and Western blotting, PLC-gamma 1 showed three-fold to fourfold more expression in carcinomas than that in normal tissues.
|
8275435 |
1994 |
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
MAPK1, SRC, SMAD4, EEF1A1, TRAF2 and PLCG1 might be responsible for the development of smoking-induced lung cancer.
|
26518718 |
2016 |
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, the prognostic model of five-gene signature (OTUD6B-AS1, PSMG3-AS1, ZBED5-AS1, SBK1, and PLCG1) was constructed to predict risk score in OC patients.
|
31462944 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Other associations of note included TNF receptor-associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77-0.92; P = 6.49 × 10(-5)) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26-0.73; P = 4.56 × 10(-4)).
|
24740199 |
2014 |
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Pleiotropic Meta-Analyses of Longitudinal Studies Discover Novel Genetic Variants Associated with Age-Related Diseases.
|
27790247 |
2016 |
Childhood Angiosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Recurrent PTPRB and PLCG1 mutations in angiosarcoma.
|
24633157 |
2014 |
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
PLCG1, SYK and PLCG2 were also involved in the B‑cell receptor signaling pathway in module B and the Fc‑epsilon RI signaling pathway in module C. In addition, AURKA (degree=39), MAD2L1 (degree=38), CDCA8 (degree=38), BUB1 (degree=37) and MELK (degree=37) exhibited higher degrees of connectivity in module F. The results of the present study suggested that the RPL8, PLCG1, PLCG2, SYK, MAD2L1, AURKA, CDCA8, BUB1 and MELK genes may be involved in OS.
|
26096802 |
2015 |
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phospholipase Cγ1 links inflammation and tumorigenesis in colitis-associated cancer.
|
29464031 |
2018 |
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
New candidate genes with a potential role in colon cancer are PLCG1 on 20q, DBC1 on 8q21, and NDGR1 on 8p24.
|
19672874 |
2009 |
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the relationship between PLCγ1 and autophagy in the human colon cancer cell line HCT116 and hepatocellular carcinoma cell line HepG2.
|
29066806 |
2017 |
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Although factors that might influence the level of PLC-gamma 1 expression in colorectal carcinomas still remain obscure, the fact that most colorectal carcinomas display elevated levels of PLC-gamma 1 expression implies that PLC-gamma 1 may play an important role in proliferation of colorectal carcinoma cells.
|
8275435 |
1994 |
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
PLC-gamma 1 may play an important role in metastasis and anti-apoptosis in human colorectal carcinomas.
|
17531112 |
2007 |
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We used robotized capillary isoelectric focusing as well as conventional immunoblotting for the comprehensive analysis of epidermal growth factor receptor signaling pathways converging on extracellular regulated kinase 1/2 (ERK1/2), AKT, phospholipase Cγ1 (PLCγ1) and c-SRC in normal mucosa compared with CRC stage II and IV.
|
27562229 |
2016 |
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PLCγ1 is a critical regulator of colitis and colorectal cancer and could further help in the development of therapy for colitis-associated cancer.
|
29464031 |
2018 |
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Additionally, immunoblot analyses revealed that the level of PLC-gamma 1 expression was considerably higher in 9 of 11 colorectal carcinomas than in adjacent normal colorectal tissues.
|
7608208 |
1995 |
Colorectal Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
NF-kappaB and Hsp70 are involved in the phospholipase Cgamma1 signaling pathway in colorectal cancer cells.
|
15996687 |
2005 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease.
|
29212778 |
2018 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Pleiotropic Meta-Analyses of Longitudinal Studies Discover Novel Genetic Variants Associated with Age-Related Diseases.
|
27790247 |
2016 |
Degenerative polyarthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Consequently, the data reveal that the inhibition of PLCγ1 may provide an attractive therapeutic target for OA therapy, implicating its binding to Akt.
|
29435116 |
2018 |
Degenerative polyarthritis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, activated ERK had no inhibitory effect on MMP-13 expression in PLCγ1-transformed OA chondrocytes.
|
26247939 |
2015 |
Dermatitis, Irritant
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phospholipase Cγ1 is required for normal irritant contact dermatitis responses and sebaceous gland homeostasis.
|
31338881 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Pleiotropic Meta-Analyses of Longitudinal Studies Discover Novel Genetic Variants Associated with Age-Related Diseases.
|
27790247 |
2016 |